Key Takeaways
- • Jeito Capital, a biopharma-focused private equity firm, appointed Magdalena Jonikas as partner and Anastasiya Sybirna as principal in London, reinforcing the firm's UK investment presence and deepening capabilities in one of the world's leading biopharma hubs.
- • Jonikas brings 10+ years of healthcare investing experience, including a stint as partner at Syncona where she managed company creation and served as interim CEO of Mosaic Therapeutics, plus prior consulting at McKinsey advising pharmaceutical clients on corporate strategy.
- • Sybirna joins from Fidelity-backed F-Prime Capital where she was senior associate focused on healthcare investments, with additional consulting experience at McKinsey and Advancy in pharmaceutical and medical products strategy.
- • The hires align with Jeito's strategy to expand investment origination, due diligence, and portfolio company support capabilities while supporting international portfolio growth.
- • Founder and CEO Dr Rafaèle Tordjman stated the appointments would enhance the firm's ability to identify and support high-growth biopharma businesses.
Summary
Jeito Capital has bolstered its London investment team through two senior appointments aimed at deepening the firm's operational footprint in the UK biopharma sector. Magdalena Jonikas joins as partner and Anastasiya Sybirna as principal, with both roles London-based and designed to strengthen the firm's investment sourcing and portfolio management capabilities.
Jonikas' appointment represents a significant hire given her track record at Syncona, where she held partner-level responsibilities across company creation, financing, and strategic development. At Syncona, she oversaw investments in therapeutics platforms including OMass Therapeutics, Kesmalea Therapeutics, and Mosaic Therapeutics, while also serving on multiple portfolio company boards. Her experience extends to interim executive leadership, notably as interim CEO of Mosaic Therapeutics, combining investment and operational expertise. Prior to Syncona, Jonikas spent several years at McKinsey & Company advising global pharmaceutical and healthcare clients on corporate strategy and conducting commercial due diligence across therapeutics, medical technology, and healthcare services verticals.
Sybirna brings complementary healthcare investment experience from F-Prime Capital, a Fidelity-backed investment firm where she worked as senior associate focused on healthcare investments. Her background includes consulting roles at both McKinsey and Advancy, where she advised pharmaceutical and medical products companies on strategic initiatives.
At Jeito, both hires will contribute to the firm's core functions: Jonikas will focus on sourcing and executing investments while supporting portfolio companies on growth and value creation initiatives, while Sybirna will support investment origination, due diligence, transaction execution, and portfolio company development. According to founder and CEO Dr Rafaèle Tordjman, the new hires will enhance Jeito's ability to identify and support high-growth biopharma businesses—a strategic priority aligned with the firm's broader expansion of its international portfolio.
Jonikas' appointment represents a significant hire given her track record at Syncona, where she held partner-level responsibilities across company creation, financing, and strategic development. At Syncona, she oversaw investments in therapeutics platforms including OMass Therapeutics, Kesmalea Therapeutics, and Mosaic Therapeutics, while also serving on multiple portfolio company boards. Her experience extends to interim executive leadership, notably as interim CEO of Mosaic Therapeutics, combining investment and operational expertise. Prior to Syncona, Jonikas spent several years at McKinsey & Company advising global pharmaceutical and healthcare clients on corporate strategy and conducting commercial due diligence across therapeutics, medical technology, and healthcare services verticals.
Sybirna brings complementary healthcare investment experience from F-Prime Capital, a Fidelity-backed investment firm where she worked as senior associate focused on healthcare investments. Her background includes consulting roles at both McKinsey and Advancy, where she advised pharmaceutical and medical products companies on strategic initiatives.
At Jeito, both hires will contribute to the firm's core functions: Jonikas will focus on sourcing and executing investments while supporting portfolio companies on growth and value creation initiatives, while Sybirna will support investment origination, due diligence, transaction execution, and portfolio company development. According to founder and CEO Dr Rafaèle Tordjman, the new hires will enhance Jeito's ability to identify and support high-growth biopharma businesses—a strategic priority aligned with the firm's broader expansion of its international portfolio.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.